



(51) International Patent Classification:

A61K 35/17 (2015.01) A01N 1/02 (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2022/015095

(22) International Filing Date:

03 February 2022 (03.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/145,235 03 February 2021 (03.02.2021) US

(71) Applicant: ALLOGENE THERAPEUTICS, INC.
[US/US]; 210 East Grand Avenue, South San Francisco,
California 94080 (US).(72) Inventors: MEDI, Muneeswara Babu; 48 Westview Ave.,
Chalfont, Pennsylvania 18914 (US). XU, Zhuojin; c/o Al-
logene Therapeutics, Inc., 210 E. Grand Avenue, South San
Francisco, California 94080 (US). LEE, Jung S.; c/o Allo-
gene Therapeutics, Inc., 210 E. Grand Avenue, South San
Francisco, California 94080 (US). NI, Yajin; 8479 Low-
er Scarborough Lane, San Diego, California 92127 (US).

LEONARD, Mark W.; c/o Allogene Therapeutics, Inc.,
210 E. Grand Avenue, South San Francisco, California
94080 (US).


(74) Agent: CHANG, Y. Elaine et al.; Allogene Therapeutics,
Inc., 210 East Grand Avenue, South San Francisco, Califor-
nia 94080 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: FORMULATIONS AND PROCESSES FOR CAR T CELL DRUG PRODUCTS

FIG. 6



(57) Abstract: Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*